PPRS will mean more patients will benefit from innovative drug treatments at a fair price to the NHS. The PPRS includes for the first time support for innovation and uptake of clinically and cost effective medicines. It also includes two provisions – more flexible pricing arrangements and more systematic use of patient access schemes – aimed at increasing patient access to medicines and ensuring the prices of medicines better reflect their value.
The objectives for the 2009 scheme, as stated in the agreement, are that it should:
Deliver value for money
Deliver value for money for the NHS by securing the provision of safe and effective medicines at reasonable prices, and encouraging the efficient development and competitive supply of medicines.
Promote a strong and profitable pharmaceutical industry that is both capable and willing to invest in sustained research and development to encourage the future availability of new and improved medicines for the benefit of patients and industry in this and other countries.
The Department of Health and industry are committed to increasing uptake and patient access for new clinically and cost-effective medicines in the NHS in a sustainable manner.
Provide stability, sustainability and predictability
To help the NHS and industry develop sustainable financial and investment strategies, the UK must remain a stable and predictable market that does not place unforeseen burdens on either party over the coming years.